{"filings":[{"id":499676,"accession_number":"0001193125-26-228958","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2026-05-18T20:21:36+00:00","items":["5.02","9.01"],"status":"ready","headline":"Innoviva directors Small and DiPaolo resign; Josephine Linden elected to board","event_type":"leadership","confidence":"high","bullets":["Derek Small (CEO of Syndeio) and Mark DiPaolo resigned May 12 to focus on Syndeio growth.","Resignations not related to any disagreement with Innoviva's operations or policies.","Josephine Linden elected to board effective May 18; qualifies as independent director.","Linden receives initial RSU of $125K, prorated RSU of $206,250, and options for 9,166 shares.","Linden will serve on Audit Committee; board cites her 25+ years at Goldman Sachs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91145,"accession_number":"0001193125-26-209044","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q1 revenue $98M (+11% YoY); IST sales surge 37%; net income $186.6M","event_type":"earnings","confidence":"high","bullets":["Total revenue $98.0M, up 11% YoY; GSK royalty revenue $58.6M (down from $61.3M).","Net product sales $41.4M (+37% YoY); US sales $34.2M led by GIAPREZA $19.7M, XACDURO $11.6M.","Net income $186.6M ($2.52 EPS) driven by $191.2M favorable fair value change in equity investments, primarily Armata Pharmaceuticals.","Repurchased 971,066 shares for $20.4M in Q1 under $125M share repurchase program.","NUZOLVENCE (zoliflodacin) FDA-approved Dec 2025; availability expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":2.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":97994000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91144,"accession_number":"0001193125-26-204243","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Innoviva shareholders reelect board, approve compensation and equity plan","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Small (56.8M for), DiPaolo (50.1M), Haimovitz (56.8M), Schlesinger (53.5M), Raifeld (58.9M).","Advisory say-on-pay approved: 56.2M for (95.2%), 2.8M against, 158k abstain.","Ratification of Deloitte & Touche as auditor for FY2026: 66.0M for (99.9%), 16.6k against.","2026 Equity Incentive Plan approved: 55.4M for (93.6%), 3.8M against, 36k abstain.","Broker non-votes of 6.8M shares on director elections and advisory compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101070,"accession_number":"0001193125-26-071974","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q4 revenue up 25% to $114.6M; net income $164.2M; NUZOLVENCE approved","event_type":"earnings","confidence":"high","bullets":["Full year 2025 revenue $411.3M (+15% YoY); net income $271.2M ($4.02 basic EPS).","Royalty revenue from GSK $250.3M; IST U.S. net product sales $119.2M (+47% YoY).","FDA approved NUZOLVENCE (zoliflodacin) for uncomplicated gonorrhea in Dec 2025.","Guidance: IST U.S. net product sales at least $150M in 2026.","$125M repurchase program initiated; 797,298 shares repurchased for $16.0M as of year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":3.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":411328000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117414,"accession_number":"0001104659-25-107014","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q3: Revenue $107.8M (+20% YoY), Net Income $89.9M, $125M Buyback","event_type":"earnings","confidence":"high","bullets":["Total revenue $107.8M (+20% YoY); GSK royalty $63.4M; net product sales $47.3M (U.S. $29.9M, +52% YoY).","Net income $89.9M ($1.30 basic EPS) vs $1.2M ($0.02) in Q3 2024; driven by $62.3M fair-value gains on equity investments.","Income from operations $34.6M, down 20% primarily due to non-recurring R&D expense.","Board authorized $125M share repurchase program; $192.5M of convertible notes converted into 11.1M shares in August.","ZEVTERA U.S. launch in July; zoliflodacin PDUFA Dec 15, 2025; investments: Armata $15M, Lyndra $10.2M, Beacon Biosignals $17.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":296715000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133824,"accession_number":"0001104659-25-074730","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q2 2025 net income $63.7M; product sales up 54% YoY; zoliflodacin PDUFA Dec 15","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net income $63.7M ($1.01 basic EPS) vs net loss of $34.7M in Q2 2024.","GSK royalty revenue $67.3M, flat YoY; IST U.S. net product sales $29.0M (+54% YoY).","ZEVTERA (ceftobiprole) commercially launched in U.S. July 2025 for three indications.","Zoliflodacin NDA accepted with Priority Review; PDUFA target date Dec 15, 2025; no AdCom planned.","Cash & equivalents $397.5M; strategic healthcare asset portfolio valued at $449.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":188915000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150559,"accession_number":"0001104659-25-051614","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Innoviva stockholders elect five directors and approve advisory compensation vote","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Derek Small, Mark DiPaolo, Jules Haimovitz, Sarah Schlesinger, Pavel Raifeld.","Non-binding advisory vote on executive compensation approved: 45.8M for, 2.1M against, 6.1M broker non-votes.","Ratification of Deloitte & Touche as auditor for 2025: 54.0M for, 118k against, 4.6k abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}